Management of Grade 1 Endometrioid Adenocarcinoma

Introduction to Treatment Approaches

The European Society of Gynaecological Oncology recommends that a 40-year-old woman with Grade 1 endometrioid adenocarcinoma be explicitly assessed for fertility desires to determine the appropriate treatment pathway, with standard surgical treatment or fertility-sparing treatment with high-dose progestins being considered based on patient preference 1, 2.

The American College of Obstetricians and Gynecologists suggests that before proceeding with any treatment, it is crucial to determine whether the patient wishes to preserve fertility, as this single factor fundamentally alters the entire treatment algorithm 1, 3.

The National Comprehensive Cancer Network recommends proceeding directly to total hysterectomy with bilateral salpingo-oophorectomy, preferably via minimally invasive approach, if fertility preservation is not desired 4, 5.
Lymphadenectomy can be considered for staging but is optional in this low-risk scenario, with sentinel lymph node dissection being an acceptable alternative to full lymphadenectomy if staging is pursued 4, 5.
The 5-year survival rate for Stage IA disease is 93%, with no adjuvant therapy required after surgery for this low-risk presentation 1, 2, 5, 6.

The European Society of Gynaecological Oncology suggests that fertility-sparing treatment with high-dose progestin therapy can be considered for patients who desire to preserve fertility, with a response rate of approximately 75% but a recurrence rate of 30-40% even among responders 1, 3.
The American College of Obstetricians and Gynecologists recommends initiating high-dose progestin therapy with either medroxyprogesterone acetate or megestrol acetate, with levonorgestrel-releasing intrauterine device being an alternative option 1, 3, 4.
Close surveillance is mandatory during and after treatment, with hysterectomy required if treatment fails or after completion of childbearing 1, 3.

The National Comprehensive Cancer Network recommends performing repeat D&C and imaging at 6 months to assess response, with immediate referral to fertility clinic and encouragement of conception if complete response is achieved 1, 3.
If no response at 6 months, proceeding immediately to standard surgical treatment is recommended, while partial response may consider maintenance treatment for an additional 6 months in patients wishing to delay pregnancy 3.

The European Society of Gynaecological Oncology notes that at age 40, the patient is at the upper limit for fertility-sparing treatment consideration, with only 4% of endometrial cancers occurring in women under 40 years of age 7, 1.
Younger women with endometrial cancer have better prognosis with increased rates of early-stage and low-grade disease 7, 1.